



CLARIFICATION ON ANNOUNCEMENT RELEASED ON SGXNET ON 30 DECEMBER 2018

The Board of Directors (the “**Board**”) of OUE Lippo Healthcare Limited (“**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcement by the Company made on 30 December 2018 titled “Entry into Management Agreements by China Merchants Lippo Hospital Management (Shenzhen) Limited” (the “**Announcement**”) and the article by the Business Times titled “OUE Lippo Healthcare unit to manage 3 China hospitals” published on 31 December 2018.

Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the Announcement.

As stated in the Announcement, the Company’s joint venture with CMSZ, CMLHM, has a right under the Management Agreements to acquire an interest in the business of each Medical Facility after completion of regulatory restructuring of each Medical Facility within the Management Period.

The Company wishes to make the following clarifications:

1. The Company understands that in order to comply with and subject to the relevant laws and regulations in China, a new hospital operating company will be set up for each Medical Facility with its own hospital licence.
2. Subject to the relevant laws and regulations in China, CMLHM has a right under the Management Agreements to acquire an interest in the new hospital operating company to be set up for each Medical Facility.

By Order of the Board
OUE Lippo Healthcare Limited

Dr Wong Weng Hong
Chief Executive Officer and Executive Director
31 December 2018

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).